Daniel E Leisman, Damian R Handisides, Laurence W Busse, Mark C Chappell, Lakhmir S Chawla, Michael R Filbin, Marcia B Goldberg, Kealy R Ham, Ashish K Khanna, Marlies Ostermann, Michael T McCurdy, Christopher D Adams, Tony N Hodges, Rinaldo Bellomo
BACKGROUND: Angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blockers (ARB) medications are widely prescribed. We sought to assess how pre-admission use of these medications might impact the response to angiotensin-II treatment during vasodilatory shock. METHODS: In a post-hoc subgroup analysis of the randomized, placebo-controlled, Angiotensin Therapy for High Output Shock (ATHOS-3) trial, we compared patients with chronic angiotensin-converting enzyme inhibitor (ACEi) use, and patients with angiotensin receptor blocker (ARB) use, to patients without exposure to either ACEi or ARB...
April 18, 2024: Critical Care: the Official Journal of the Critical Care Forum